Zhishuang Gao
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer.
Journal: Biomarker research
Published: April 04, 2025
USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: January 31, 2024
m6A modification of lncRNA ABHD11-AS1 promotes colorectal cancer progression and inhibits ferroptosis through TRIM21/IGF2BP2/ FOXM1 positive feedback loop.
Journal: Cancer letters
Published: January 27, 2024
TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors.
Journal: British journal of cancer
Published: June 20, 2023
m6A Modification of Long Non-Coding RNA HNF1A-AS1 Facilitates Cell Cycle Progression in Colorectal Cancer via IGF2BP2-Mediated CCND1 mRNA Stabilization.
Journal: Cells
Published: August 05, 2022
N6-methyladenosine-modified USP13 induces pro-survival autophagy and imatinib resistance via regulating the stabilization of autophagy-related protein 5 in gastrointestinal stromal tumors.
Journal: Cell death and differentiation
Published: July 26, 2022
Deubiquitylation of Rab35 by USP32 promotes the transmission of imatinib resistance by enhancing exosome secretion in gastrointestinal stromal tumours.
Journal: Oncogene
Published: July 21, 2022
N6-methyladenosine modification regulates imatinib resistance of gastrointestinal stromal tumor by enhancing the expression of multidrug transporter MRP1.
Journal: Cancer letters
Published: October 02, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026